GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and ...

PridCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, designed to hinder the SARS-CoV-2 virus’s ability to replicate. Clinical ...

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed. When you purchase through links on our ...

AIM ImmunoTech Inc. announced progress in its clinical development of Ampligen® (rintatolimod), particularly in addressing critical unmet medical needs in areas like pancreatic cancer and Long-COVID.

Moderna’s next-gen COVID vaccine notched a higher immune response than its licensed counterpart, passing a phase 3 test. No data accompanied the company’s announcement Tuesday, with Moderna saying ...